We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Oxford University’s Rapid COVID-19 Test Detects SARS-CoV-2 Within 30-45 Minutes

By LabMedica International staff writers
Posted on 17 Jul 2020
Scientists have developed a rapid test which detects the presence of the SARS-CoV-2 virus and could be adapted for use in settings ranging from community care, schools, airports or home self-testing.

The test for the detection of COVID-19 has been developed by the University of Oxford’s Department of Engineering Science and Oxford Suzhou Centre for Advanced Research (OSCAR Oxford, UK). More...
The Oxford-OSCAR team has designed primers with high specificity to confirm presence of the virus in infected people, adapted from an established technology known as RT-LAMP (reverse transcription-loop mediated isothermal amplification). It is a simplified one-step version of a viral RNA test and can be used in the field without specialist equipment or training. The simple colorimetric result is read by eye or fluorescent display, meaning there is no need for additional tools to analyze results. A Bluetooth-linked fluorescent detection instrument can link the test result into a laboratory information system, so that test results can be tracked.

The test produces results within 30-45 minutes and detects SARS-CoV-19 with great sensitivity and specificity using throat/nasal swabs directly to identify individuals carrying the virus. Clinical trials have generated comparable results with laboratory tests, demonstrating reliability, and the results will be published shortly. The test will soon be certified with CE-mark. It will be available in quantity with the commercial product name Oxsed RaViD Direct at a cost of no more than GBP 20 per test, which is considerably cheaper than most of the products currently on market.

“By designing the specific primers and controlling the biochemical reaction, we are able to eliminate the non-specific reactions that cause false positives and make our RT-LAMP test robust. And the Oxford test can be transported and stored at ambient temperature without need for cold chain, which makes shipping and distribution much easier,” said Professor Wei Huang who designed the primers to target the viral RNA.

“Our test is ideal for use in community or field settings by lay persons and allows immediate decisions to be made. Immediate applications are: returning to work/education (i.e. schools, universities, companies) and making quarantine decision (e.g. care homes, hospitals, temporary migrants, tourists). Use of such a test could be crucial to economic recovery globally,” said Prof Zhanfeng Cui, the Director of OSCAR.

Related Links:
University of Oxford


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The initiative aims to speed next-generation diagnostic development during early pathogen emergence (photo courtesy of 123RF)

Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss

Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.